Related Experiment Video
Updated: Jun 13, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Investigation through naphtho[2,3-a]pyrene on mutated EGFR mediated autophagy in NSCLC: Cellular model system
Nikhil Samarth1, Pooja Gulhane1, Shailza Singh1
1Systems Medicine Laboratory, Biotechnology Research and Innovation Council-National Centre for Cell Science (BRIC-NCCS), NCCS Complex, Pune, India.
Abstract:
Mutant epidermal growth factor receptor (EGFR) signaling has emerged as a key cause of carcinogenesis and therapy resistance in non-small cell lung cancer (NSCLC), which continues to pose a serious threat to world health. In this study, we aimed to elucidate the complex molecular pathways of EGFR-mediated autophagy signaling in NSCLC. We identified naphtho[2,3-a]pyrene, an anthraquinolone derivative, to be a promising investigational drug that targets EGFR-mediated autophagy using a cellular model system. By utilizing systems biology, we developed a computational model that explained the signaling of EGFR-mediated autophagy and identified critical crosstalk sites that could be inhibited therapeutically. As a lead compound, naphtho[2,3-a]pyrene was confirmed by molecular docking experiments. It was found to be cytotoxic to NSCLC cells, impact migration, induce apoptosis, and arrest cell cycle, both on its own and when combined with standard drugs. The anticancer efficacy of naphtho[2,3-a]pyrene was validated in vivo on CDX nude mice. It showed synergistic activity against NSCLC when coupled with gefitinib, chloroquine, and radiation. Altogether, our study highlights naphtho[2,3-a]pyrene's therapeutic promise in NSCLC by focusing on EGFR-mediated autophagy and providing a new strategy to fight drug resistance and tumor survival.
Insights
A novel compound, naphtho[2,3-a]pyrene, effectively targets epidermal growth factor receptor (EGFR)-mediated autophagy in non-small cell lung cancer (NSCLC). This drug shows promise in overcoming therapy resistance and improving survival rates for NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Mutant epidermal growth factor receptor (EGFR) signaling drives non-small cell lung cancer (NSCLC) development and treatment resistance.
- EGFR-mediated autophagy plays a critical role in NSCLC pathogenesis and survival.
Purpose of the Study:
- To elucidate the molecular pathways of EGFR-mediated autophagy in NSCLC.
- To identify and validate a novel therapeutic agent targeting this pathway.
Main Methods:
- Systems biology and computational modeling to analyze EGFR-mediated autophagy signaling.
- Molecular docking and in vitro assays to evaluate naphtho[2,3-a]pyrene's efficacy.
- In vivo studies in CDX nude mice to confirm anticancer activity.
Main Results:
- Naphtho[2,3-a]pyrene, an anthraquinolone derivative, was identified as a promising drug candidate.
- The compound demonstrated cytotoxicity, inhibited migration, induced apoptosis, and caused cell cycle arrest in NSCLC cells.
- In vivo studies confirmed naphtho[2,3-a]pyrene's anticancer efficacy and synergistic activity with standard treatments.
Conclusions:
- Naphtho[2,3-a]pyrene represents a potential therapeutic strategy for NSCLC by targeting EGFR-mediated autophagy.
- This compound offers a new approach to combat drug resistance and enhance tumor survival in NSCLC.
- The study provides a validated preclinical basis for naphtho[2,3-a]pyrene in NSCLC treatment.
